• Title/Summary/Keyword: cumulative dose

Search Result 237, Processing Time 0.026 seconds

A Retrospective Analysis of the Effectiveness of Taking Gambi-tang in Overweight and Obese Adults (과체중 및 비만 성인 대상 감비탕 복용 효과에 대한 후향적 분석)

  • Park, Han-song;Yoo, Hee-jung;Ha, Ji-su;Park, Hyun-seo;Seo, Ho-seok;Kim, Jin-won
    • The Journal of Internal Korean Medicine
    • /
    • v.43 no.3
    • /
    • pp.413-422
    • /
    • 2022
  • Objectives: To investigate the weight loss effect of Gambi-tang in obese and overweight adults. Methods: From September 1, 2016 to December 31, 2021, a retrospective chart analysis was conducted on adult men and women who were prescribed Gambi-tang to address obesity and overweight in the National Medical Center (NMC). Partial analysis by age, obesity (Body Mass Index, BMI), duration of dose, and cumulative dose was also conducted. Results: The weight and BMI of the study subjects showed a significant decrease of more than 5% on average before and after treatment. In an analysis of age, significant differences by age could not be confirmed. In the analysis by obesity level, the effect of reducing weight, body fat, and abdominal fat rates in the obese and highly obese groups was greater than in the normal and overweight groups. There was no significant difference by group in the analysis by dosage period. In the analysis by cumulative dose, the greater the cumulative dose up to 1,800 g, the greater the decrease in weight and body fat. The side effect that patients appealed to the most was misjudgment, but not to a serious extent. Conclusions: Gambi-tang has been shown to be effective in weight and body fat loss for both obese and overweight adult men and women.

Evaluation of Usability and Radiation Dose Measurement Using Personal Radiation Exposure Dosimeter (방사선 개인피폭선량계를 이용한 피폭선량 측정 및 유용성 평가)

  • Kang, In-Seog;Ahn, Sung-Min
    • The Journal of the Korea Contents Association
    • /
    • v.14 no.11
    • /
    • pp.864-870
    • /
    • 2014
  • To propose a basis for the selection of personal dosimeters to measure radiation dose administration of radiation workers as a way to evaluate the usefulness dosimeter. For the dosimetry of the radiation workers 2012, during 1 year, 30 were radiation workers to measure personal dose. By personal exposure is measured cumulative dose, is investigated the performance of the TLD, PLD, OSLD. And comparing the measured value of each dosimeter dose and analyzed. Medical institutions, inspection work and quarterly confirmed the cumulative exposure dose of radiation workers. Using DAP and Ion-Chamber, to measure to compare TLD, PLD, OSLD dosimeter performance. A comparison of the directly through the X-ray dosimeter and The absolute value of the Ion-Chamber, OSLD more similar than in the TLD and PLD showed the dose values so the excellent ability to measure the results. Also in radiation generating area dose of radiation workers is higher than that in OSLD. Consequently, in terms of the individual exposure management OSLD is appropriated and beneficial than others.

Organ dose reconstruction for the radiation epidemiological study of Korean radiation workers: The first dose evaluation for the Korean Radiation Worker Study (KRWS)

  • Tae-Eun Kwon;Areum Jeong;Wi-Ho Ha;Dalnim Lee;Songwon Seo;Junik Cho;Euidam Kim;Yoonsun Chung;Sunhoo Park
    • Nuclear Engineering and Technology
    • /
    • v.55 no.2
    • /
    • pp.725-733
    • /
    • 2023
  • The Korea Institute of Radiological and Medical Sciences has started a radiation epidemiological study, titled "Korean Radiation Worker Study," to evaluate the health effects of occupational exposure to radiation. As a part of this study, we investigated the methodologies and results of reconstructing organ-specific absorbed doses based on personal dose equivalent, Hp(10), reported from 1984 to 2019 for 20,605 Korean radiation workers. For the organ dose reconstruction, representative exposure scenarios (i.e., radiation energy and exposure geometry) were first determined according to occupational groups, and dose coefficients for converting Hp(10) to organ absorbed doses were then appropriately taken based on the exposure scenarios. Individual annual doses and individual cumulative doses were reconstructed for 27 organs, and the highest values were observed in the thyroid doses (on average 0.77 mGy/y and 10.47 mGy, respectively). Mean values of individual cumulative absorbed doses for the red bone marrow, colon, and lungs were 7.83, 8.78, and 8.43 mSv, respectively. Most of the organ doses were maximum for industrial radiographers, followed by nuclear power plant workers, medical workers, and other facility workers. The organ dose database established in this study will be utilized for organ-specific risk estimation in the Korean Radiation Worker Study.

Comparison on Analgesic Effect of Morphine and Meperidine with Patient-Controlled Analgesia for the Pain Relief after Cesarean Section (제왕절개술후 통증조절을 위해 PCA를 이용한 Morphine과 Meperidine의 제통효과 비교)

  • Lee, Byung-Ho;Lee, Chul-Woo;Kim, Chang-Jae;Chung, Mee-Young;Park, Dong-Sook;Chea, Jun-Seuk
    • The Korean Journal of Pain
    • /
    • v.9 no.1
    • /
    • pp.166-171
    • /
    • 1996
  • The purpose of this study is to compare the postoperative analgesic effect of morphine and meperidine, employing intravenous patient controlled analgesia after cesarean section. Among fifty nine parturients undergoing cesarean section with general anesthesia, 32 were administered morphine designated as 'morphine group', and 27 parturient administered meperidine as 'meperidine' group, during 48 hours after commencement of PCA. Doses administered, based on potency for this setting, were equivalent to 1 mg morphine or 10 mg meperidine. Loading dose was administered when parturient first complained of pain after cesarean section. This was followed with bolus dose, 1 mg for morphine group and 10 mg for meperidine group, with a lockout interval of 8 minutes between doses wherever parturient requested additional analgesia. Visual analog scale(VAS) pain scores during rest were significantly lower at only 1 and 2 hour for the meperidine group, than morphine group. Loading dose and cumulative dose at 1, 2 and 3 hours were significantly lower for meperidine group than the morphine group. There were no significant difference in total dose and hourly dose for 48 hours and cumulative dose at 6, 12, 24, and 48 hours between both groups. More than 90% of the parturients from both groups were satisfied with the analgesic effects of pain relief. Morphine group experienced side effects such as: pruritus, sedation and dizziness. Meperidine group had sedation, dizziness, nausea and local irritation. Neither group required any specific treatment for any of the above side effects. We conclude that meperidine had greater analgesic effect at early stage of post-operative period.

  • PDF

Patient Radiation Dose Values During Interventional Cardiology Examinations in University Hospital, Korea (심장혈관 조영술과 심장혈관 인터벤션의 환자 선량 평가)

  • Kim, Jung-Su;Lee, Joun-Hyuk;Jung, Hae-Kyoung;Kim, Jung-Min;Cho, Byung Ryul
    • Journal of radiological science and technology
    • /
    • v.39 no.1
    • /
    • pp.27-33
    • /
    • 2016
  • The use of cardiac angiography (CA) and the interventional procedures is rapidly increasing due to the increase in modern adult diseases. Cardiovascular intervention (CI) is an examination method where radiation is applied to the same area for a long period, and thus may cause skin injury. In this study, we investigate the diagnostic reference level (DRL) of the cardiovascular intervention (CI) carried out by medical institutions and use it as a tool to reduce patient exposure dose. In this study, the DRL was set by acquiring information about the cumulative fluoroscopy time, cumulative fluoroscopy dose-area product (DAP), radiography DAP, cumulative DAP, air kerma, number of video clips, and the total number of images from the cardiac angiography and interventional procedures performed on 147 patients. The DAPs corresponding to the DRL of cardiac angiography(CA) and that of the interventional procedures were shown to be $44.4Gy{\cdot}cm2$ and $298.6Gy{\cdot}cm2$, respectively; the corresponding DRLs of fluoroscopy time were shown to be 191.5s and 1935.3s, respectively. A DRL is not a strict upper bound for radiation exposure. However, the process of setting, enacting, and reviewing the DRLs for the dose by medical institutions will contribute to a reduction in the unnecessary exposure dose of patients.

Two Cases of Severe Pancytopenia Associated with Low-Dose Methotrexate Therapy in Patients with Chronic Kidney Disease and Rheumatoid Arthritis (류마티스 관절염을 가진 만성신질환 환자에서 저용량 methotrexate 투여 후 발생한 중증 범혈구 감소증 2예)

  • Kim, Hong-Ik;Lee, Woo-Hyun;Oh, Jang-Seok;Hong, Hyo-Rim;Lee, In-Hee
    • Journal of Yeungnam Medical Science
    • /
    • v.28 no.1
    • /
    • pp.60-69
    • /
    • 2011
  • Due to its efficacy and tolerability, low dose oral methotrexate (MTX) therapy has been widely used for treatment of rheumatoid arthritis (RA). However, it can rarely cause serious, life-threatening hematologic toxicities, such as pancytopenia. We report here on two patients with chronic kidney disease (CKD), who developed severe pancytopenia after 5 years (cumulative dose 1,240 mg) and 4 years (cumulative dose 1,320 mg) of low dose MTX therapy for treatment of RA, respectively. Both patients presented with renal insufficiency, hypoalbuminemia, concurrent use of nonsteroidal anti-inflammatory drugs, and elevated mean corpuscular volume of red blood cells (RECs), all of which are known as risk factors of MTX-induced pancytopenia. Despite receiving treatment, which included REC and platelet transfusions, antibiotic therapy, granulocyte colony stimulating factor, and leucovorin rescue, one patient died of sepsis. Based on our case study, prompt investigation of risk factors associated with MTX toxicity is required for all patients receiving MTX therapy. MTX treatment, even at a low dose, should be discontinued in patients with advanced CKD.

  • PDF

Possible Biomarker Gene for Radiation Workers in Hospital

  • Jin, Young-Woo;Jeong, Mee-Seon;Moon, Kien;Lee, Chee-Young;Bae, Sang-Woo;Choi, Soo-Yong;Lee, Yun-Sil
    • Molecular & Cellular Toxicology
    • /
    • v.5 no.2
    • /
    • pp.165-171
    • /
    • 2009
  • Biomarkers indicating past exposure to radiation have not yet been entirely satisfactory. In this study, we validated several genes reported as radiation response genes, as biomarkers to detect past exposure to radiation in occupationally exposed workers, especially workers in the medical field. A total of 54 radiation workers in hospital were investigated for radiation exposure dose. Their average radiation dose of recent one year was 1.09 mSv ($\pm$1.63) with a 10.63 mSv ($\pm$12.91) cumulative dose. The results of the multiple regression analysis for the various variables indicate that the Hsc70 (P=0.0292) and ORAL (P=0.0045) may be candidate biomarkers for the recent 1 year radiation exposure in radiation workers, whereas AEN (P=0.0334) and PGAMI (P=0.0003) might be for cumulative exposure.

Radiosurgery for Recurrent Brain Metastases after Whole-Brain Radiotherapy : Factors Affecting Radiation-Induced Neurological Dysfunction

  • Gwak, Ho-Shin;Yoo, Hyung-Jun;Youn, Sang-Min;Lee, Dong-Han;Kim, Mi-Sook;Rhee, Chang-Hun
    • Journal of Korean Neurosurgical Society
    • /
    • v.45 no.5
    • /
    • pp.275-283
    • /
    • 2009
  • Objective : We retrospectively analyzed survival, local control rate, and incidence of radiation toxicities after radiosurgery for recurrent metastatic brain lesions whose initial metastases were treated with whole-brain radiotherapy. Various radiotherapeutical indices were examined to suggest predictors of radiation-related neurological dysfunction. Methods : In 46 patients, total 100 of recurrent metastases (mean 2.2, ranged 1-10) were treated by CyberKnife radiosurgery at average dose of 23.1 Gy in 1 to 3 fractions. The median prior radiation dose was 32.7 Gy, the median time since radiation was 5.0 months, and the mean tumor volume was $12.4cm^3$. Side effects were expressed in terms of radiation therapy oncology group (RTOG) neurotoxicity criteria. Results : Mass reduction was observed in 30 patients (65%) on MRI. After the salvage treatment, one-year progression-free survival rate was 57% and median survival was 10 months. Age(<60 years) and tumor volume affected survival rate(p=0.03, each). Acute (${\leq}$1 month) toxicity was observed in 22% of patients, subacute and chronic (>6 months) toxicity occurred in 21 %, respectively. Less acute toxicity was observed with small tumors (<$10cm^3$. p=0.03), and less chronic toxicity occurred at lower cumulative doses (<100 Gy, p=0.004). "Radiation toxicity factor" (cumulative dose times tumor volume of <1,000 Gy${\times}cm^3$) was a significant predictor of both acute and chronic CNS toxicities. Conclusion: Salvage CyberKnife radiosurgery is effective for recurrent brain metastases in previously irradiated patients, but careful evaluation is advised in patients with large tumors and high cumulative radiation doses to avoid toxicity.

Peripapillary Retinal Nerve Fiber Layer Thicknesses Did Not Change in Long-term Hydroxychloroquine Users

  • Lee, Eun Jung;Kim, Sang Jin;Han, Jong Chul;Eo, Doo Ri;Lee, Min Gyu;Ham, Don-Il;Kang, Se Woong;Kee, Changwon;Lee, Jaejoon;Cha, Hoon-Suk;Koh, Eun-Mi
    • Korean Journal of Ophthalmology
    • /
    • v.32 no.6
    • /
    • pp.459-469
    • /
    • 2018
  • Purpose: To evaluate changes in the peripapillary retinal nerve fiber layer (RNFL) thicknesses using spectral-domain optical coherence tomography (SD-OCT) in hydroxychloroquine (HCQ) users. Methods: The medical records of HCQ users were retrospectively reviewed. In these HCQ users, an automated perimetry, fundus autofluorescence photography, and SD-OCT with peripapillary RNFL thickness measurements were performed. The peripapillary RNFL thicknesses were compared between the HCQ users and the control groups. The relationships between the RNFL thicknesses and the duration or cumulative dosage of HCQ use were analyzed. Results: This study included 77 HCQ users and 20 normal controls. The mean duration of HCQ usage was $63.6{\pm}38.4$ months, and the cumulative dose of HCQ was $528.1{\pm}3.44g$. Six patients developed HCQ retinopathy. Global and six sectoral RNFL thicknesses of the HCQ users did not significantly decrease compared to those of the normal controls. No significant correlation was found between the RNFL thickness and the duration of use or cumulative dose. The eyes of those with HCQ retinopathy had temporal peripapillary RNFL thicknesses significantly greater than that of normal controls. Conclusions: The peripapillary RNFL thicknesses did not change in the HCQ users and did not correlate with the duration of HCQ use or cumulative doses of HCQ. RNFL thickness is not a useful biomarker for the early detection of HCQ retinal toxicity.

Renal Impairment Associated with Weekly Cisplatin and Gemcitabine Combination Therapy for Treatment of Biliary Tract Cancer

  • Galam Leem;Hee Seung Lee;Moon Jae Chung;Jeong Youp Park;Si Young Song;Seungmin Bang
    • Journal of Digestive Cancer Research
    • /
    • v.4 no.1
    • /
    • pp.36-38
    • /
    • 2016
  • Biliary tract cancer, a relatively rare disease, is usually found in an unresectable stage. Weekly cisplatin plus gemcitabine has been applied as a standard first-line therapy for advanced biliary tract cancer, but almost up to 3-5% patients experience drug induced renal impairment. Many anticancer medication guidelines recommend drug adjustment when kidneys are damaged, but weekly cisplatin is somewhat low dose so that there is a controversy on reducing the dose. And it is known that the cumulative dose of cisplatin is the most important factor contributing to renal impairment. Therefore, clinicians face troubles whether or not to maintain the chemotherapy. Here, we reported a patient whose renal function (eGFR) had been decreased as the number of chemotherapy increased, so her chemotherapy should be stopped. Since we held the chemotherapy on her, the disease progressed aggressively. Weekly cisplatin regimen is just 25 mg/m2, so it may be meaningless to reduce this dose, and it is well known that cumulative dose of cisplatin is the most important factor contributing to renal impairment, it is better not to use cisplatin anymore. Therefore, we recommend that if the patient responds well to weekly cisplatin plus gemcitabine regimen, it would be beneficial to use gemcitabine alone.

  • PDF